Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02187055
Registration number
NCT02187055
Ethics application status
Date submitted
8/07/2014
Date registered
10/07/2014
Date last updated
27/06/2018
Titles & IDs
Public title
An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate
Query!
Scientific title
A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis
Query!
Secondary ID [1]
0
0
2014-000358-13
Query!
Secondary ID [2]
0
0
A3921187
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ORAL STRATEGY
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rhematoid Arthritis
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Tofacitinib with methotrexate
Treatment: Drugs - Tofacitinib without methotrexate
Other interventions - Adalimumab with methotrexate
Experimental: Tofacitinib 5 mg twice daily with methotrexate -
Experimental: Tofacitinib 5 mg twice daily monotherapy -
Active Comparator: Adalimumab with methotrexate -
Treatment: Drugs: Tofacitinib with methotrexate
Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
Treatment: Drugs: Tofacitinib without methotrexate
Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
Other interventions: Adalimumab with methotrexate
Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Achieving American College of Rheumatology Criteria 50% Improvement (ACR50) Response at Month 6
Query!
Assessment method [1]
0
0
ACR50 is a greater than or equal to (=) 50 percent (%) improvement in tender joint count (TJC) or swollen joint count (SJC) and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment (PGA) of disease activity, 2) participant's assessment (PtGA) of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein (CRP) at each visit.
Query!
Timepoint [1]
0
0
Month 6
Query!
Secondary outcome [1]
0
0
Change From Baseline in Simplified Disease Activity Index (SDAI) Value at Month 6
Query!
Assessment method [1]
0
0
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 centimeter (cm) visual analogue scale (VAS) (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI less than or equal to (=) 3.3 indicates disease remission, >3.4 to 11 indicates low disease activity, >11 to 26 indicates moderate disease activity, and >26 indicates high disease activity.
Query!
Timepoint [1]
0
0
Month 6
Query!
Secondary outcome [2]
0
0
Change From Baseline in Clinical Disease Activity Index (CDAI) Value at Month 6
Query!
Assessment method [2]
0
0
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI =2.8 indicates disease remission, >2.8 to 10 indicates low disease activity, >10 to 22 indicates moderate disease activity, and >22 indicates high disease activity.
Query!
Timepoint [2]
0
0
Month 6
Query!
Secondary outcome [3]
0
0
Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including CRP at Month 6
Query!
Assessment method [3]
0
0
DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014* PtGA (millimeters [mm]) + 0.96. Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-4 (CRP) =3.2 indicates low disease activity, >3.2 to 5.1 indicates moderate to high disease activity, and less than (<) 2.6 indicates remission.
Query!
Timepoint [3]
0
0
Month 6
Query!
Secondary outcome [4]
0
0
Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including Erythrocyte Sedimentation Rate (ESR) at Month 6
Query!
Assessment method [4]
0
0
DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014* PtGA (mm). Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-3 (ESR) =3.2 indicates low disease activity, >3.2 to 5.1 indicates moderate to high disease activity, and <2.6 indicates remission.
Query!
Timepoint [4]
0
0
Month 6
Query!
Secondary outcome [5]
0
0
Percentage of Participants Achieving Observed American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean Remission Criteria at Month 6
Query!
Assessment method [5]
0
0
To meet the ACR-EULAR Boolean remission criteria, a participant must satisfy all of the following: TJC =1 and SJC =1 (both based on a 28-joint assessment), CRP =1 mg/dL, and PtGA =1 on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity).
Query!
Timepoint [5]
0
0
Month 6
Query!
Secondary outcome [6]
0
0
Percentage of Participants Achieving SDAI =3.3 at Month 6
Query!
Assessment method [6]
0
0
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI =3.3 indicates disease remission.
Query!
Timepoint [6]
0
0
Month 6
Query!
Secondary outcome [7]
0
0
Percentage of Participants Achieving CDAI =2.8 at Month 6
Query!
Assessment method [7]
0
0
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI =2.8 indicates disease remission.
Query!
Timepoint [7]
0
0
Month 6
Query!
Secondary outcome [8]
0
0
Percentage of Participants Achieving DAS28-4 (ESR) <2.6 at Month 6
Query!
Assessment method [8]
0
0
DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014* PtGA (mm). Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (ESR) <2.6 indicates disease remission.
Query!
Timepoint [8]
0
0
Month 6
Query!
Secondary outcome [9]
0
0
Percentage of Participants Achieving DAS28-4 (CRP) <2.6 at Month 6
Query!
Assessment method [9]
0
0
DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014* PtGA (mm) + 0.96. Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (CRP) <2.6 indicates remission.
Query!
Timepoint [9]
0
0
Month 6
Query!
Secondary outcome [10]
0
0
Percentage of Participants Achieving SDAI =11 at Month 6
Query!
Assessment method [10]
0
0
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI =3.3 indicates disease remission, >3.4 to 11 indicates low disease activity.
Query!
Timepoint [10]
0
0
Month 6
Query!
Secondary outcome [11]
0
0
Percentage of Participants Achieving CDAI =10 at Month 6
Query!
Assessment method [11]
0
0
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI =2.8 indicates disease remission, >2.8 to 10 indicates low disease activity.
Query!
Timepoint [11]
0
0
Month 6
Query!
Secondary outcome [12]
0
0
Percentage of Participants Achieving DAS28-4 (ESR) =3.2 at Month 6
Query!
Assessment method [12]
0
0
DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014* PtGA (mm). Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (ESR) =3.2 indicates low disease activity.
Query!
Timepoint [12]
0
0
Month 6
Query!
Secondary outcome [13]
0
0
Percentage of Participants Achieving DAS28-4 (CRP) =3.2 at Month 6
Query!
Assessment method [13]
0
0
DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014* PtGA + 0.96. Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-4 (CRP) =3.2 indicates low disease activity.
Query!
Timepoint [13]
0
0
Month 6
Query!
Secondary outcome [14]
0
0
Percentage of Participants Achieving American College of Rheumatology Criteria 20% Improvement (ACR20) Response at Month 6
Query!
Assessment method [14]
0
0
ACR20 response is a =20% improvement in TJC or SJC and 20% improvement in 3 of the following 5 criteria: 1) PGA of disease activity, 2) PtGA of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit.
Query!
Timepoint [14]
0
0
Month 6
Query!
Secondary outcome [15]
0
0
Percentage of Participants Achieving American College of Rheumatology Criteria 70% Improvement (ACR70) Response at Month 6
Query!
Assessment method [15]
0
0
ACR70 response is a =70% improvement in TJC or SJC and 70% improvement in 3 of the following 5 criteria: 1) PGA of disease activity, 2) PtGA of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit.
Query!
Timepoint [15]
0
0
Month 6
Query!
Secondary outcome [16]
0
0
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Month 6
Query!
Assessment method [16]
0
0
The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dressing and grooming, arising, eating, walking, reach, grip, hygiene and other activities over the past week. Each activity category consists of 2 to 3 items. Each item is scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity requiring assistance from another individual or the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty.
Query!
Timepoint [16]
0
0
Month 6
Query!
Secondary outcome [17]
0
0
Percentage of Participants Achieving an HAQ-DI Decrease of at Least 0.22 at Month 6
Query!
Assessment method [17]
0
0
The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dressing and grooming, arising, eating, walking, reach, grip, hygiene and other activities over the past week. Each activity category consists of 2 to 3 items. Each item is scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity requiring assistance from another individual or the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. A decrease of 0.22 or more is considered a positive response.
Query!
Timepoint [17]
0
0
Month 6
Query!
Secondary outcome [18]
0
0
Change From Baseline in the Short-Form-36 (SF-36) Health Survey, Physical Component Score at Month 6
Query!
Assessment method [18]
0
0
The SF-36 health survey is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based scores for both the SF-36 version 2 (v2) and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher PCS score represents better physical health status.
Query!
Timepoint [18]
0
0
Month 6
Query!
Secondary outcome [19]
0
0
Change From Baseline in the SF-36 Health Survey, Mental Component Score at Month 6
Query!
Assessment method [19]
0
0
The SF-36 health survey is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The health domains are aggregated into two summary scores known as the PCS score and the MCS score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher MCS score represents better physical health status.
Query!
Timepoint [19]
0
0
Month 6
Query!
Secondary outcome [20]
0
0
Change From Baseline in the SF-36 Health Survey, Physical Functioning Domain Score at Month 6
Query!
Assessment method [20]
0
0
SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 10 items of the physical functioning scale represent levels and kinds of limitations between extremes of physical activities, including lifting and carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence and extent of physical limitations using a 3-level response continuum. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher physical functioning domain score represents better physical functioning.
Query!
Timepoint [20]
0
0
Month 6
Query!
Secondary outcome [21]
0
0
Change From Baseline in the SF-36 Health Survey, Role Physical Domain Score at Month 6
Query!
Assessment method [21]
0
0
SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 4-item role physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; and d) accomplishing less. Items in the role physical scale are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher role physical domain score represents better role physical functioning.
Query!
Timepoint [21]
0
0
Month 6
Query!
Secondary outcome [22]
0
0
Change From Baseline in the SF-36 Health Survey, Bodily Pain Domain Score at Month 6
Query!
Assessment method [22]
0
0
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher bodily pain domain score represents less bodily pain.
Query!
Timepoint [22]
0
0
Month 6
Query!
Secondary outcome [23]
0
0
Change From Baseline in the SF-36 Health Survey, General Health Domain Score at Month 6
Query!
Assessment method [23]
0
0
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The general health scale consists of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher general health domain score represents better general health perceptions.
Query!
Timepoint [23]
0
0
Month 6
Query!
Secondary outcome [24]
0
0
Change From Baseline in the SF-36 Health Survey, Vitality Domain Score at Month 6
Query!
Assessment method [24]
0
0
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher vitality domain score represents better vitality.
Query!
Timepoint [24]
0
0
Month 6
Query!
Secondary outcome [25]
0
0
Change From Baseline in the SF-36 Health Survey, Social Functioning Domain Score at Month 6
Query!
Assessment method [25]
0
0
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 2-item social functioning scale assesses health-related effects on quantity and quality of social activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher social functioning domain score represents better social functioning.
Query!
Timepoint [25]
0
0
Month 6
Query!
Secondary outcome [26]
0
0
Change From Baseline in the SF-36 Health Survey, Role Emotional Domain Score at Month 6
Query!
Assessment method [26]
0
0
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 3-item role emotional scale assesses mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. All 3 items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher role emotional domain score represents better role emotional functioning.
Query!
Timepoint [26]
0
0
Month 6
Query!
Secondary outcome [27]
0
0
Change From Baseline in the SF-36 Health Survey, Mental Health Domain Score at Month 6
Query!
Assessment method [27]
0
0
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. All items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher mental health domain score represents better mental health functioning.
Query!
Timepoint [27]
0
0
Month 6
Query!
Secondary outcome [28]
0
0
Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Questionnaire at Month 6
Query!
Assessment method [28]
0
0
The WPAI: Rheumatoid Arthritis is a 6 item questionnaire that is specific for rheumatoid arthritis and yields four types of scores: absenteeism, presenteesism (impairment at work/reduced job effectiveness), work productivity loss and activity impairment. WPAI outcomes are expressed as impairment percentages ranging from 0 to 100, with higher numbers indicating greater impairment and less productivity.
Query!
Timepoint [28]
0
0
Month 6
Query!
Secondary outcome [29]
0
0
Change From Baseline in the EuroQol European Quality of Life-5 Dimensions (EuroQol EQ-5D) at Month 6
Query!
Assessment method [29]
0
0
The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). This profile of scores across the 5-dimensions (e.g. 11231, 33212, etc.) is transformed into a single health utility score using a formula developed by the EuroQol Group that applies country specific preference weights. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rated the current health state on a scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicating a better health state.
Query!
Timepoint [29]
0
0
Month 6
Query!
Secondary outcome [30]
0
0
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale Total Score at Month 6
Query!
Assessment method [30]
0
0
FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). The larger the participant's response (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).
Query!
Timepoint [30]
0
0
Month 6
Query!
Eligibility
Key inclusion criteria
- Have moderate to severe rheumatoid arthritis
- On methotrexate but inadequately controlled
- Subjects must not have active tuberculosis or an inadequately treated tuberculosis
infection
- Subjects must use contraception
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Subjects who have been previously treated with adalimumab or Tofacitinib
- Subjects with any current malignancy or a history of malignancy, with the exception of
adequately treated or excised non metastatic basal cell or squamous cell cancer of the
skin or cervical carcinoma in situ.
- Subjects with specific laboratory test abnormalities
- Subjects with specific types of infections
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/08/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/12/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1152
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Royal Prince Alfred Hospital - Camperdown
Query!
Recruitment hospital [2]
0
0
Pacific Private Clinic - Southport
Query!
Recruitment hospital [3]
0
0
QML Pathology - Southport
Query!
Recruitment hospital [4]
0
0
The Queen Elizabeth Hospital - Woodville South
Query!
Recruitment hospital [5]
0
0
Emeritus Research - Malvern East
Query!
Recruitment hospital [6]
0
0
RK Will Pty Ltd - Victoria Park
Query!
Recruitment postcode(s) [1]
0
0
2050 - Camperdown
Query!
Recruitment postcode(s) [2]
0
0
4215 - Southport
Query!
Recruitment postcode(s) [3]
0
0
5011 - Woodville South
Query!
Recruitment postcode(s) [4]
0
0
3145 - Malvern East
Query!
Recruitment postcode(s) [5]
0
0
6100 - Victoria Park
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Idaho
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Louisiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Mississippi
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Missouri
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
New York
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
North Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
North Dakota
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Oklahoma
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Pennsylvania
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
South Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Tennessee
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Texas
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Washington
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Buenos Aires
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Tucuman
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
San Juan
Query!
Country [26]
0
0
Bosnia and Herzegovina
Query!
State/province [26]
0
0
Republika Srpska
Query!
Country [27]
0
0
Bosnia and Herzegovina
Query!
State/province [27]
0
0
Tuzla
Query!
Country [28]
0
0
Bulgaria
Query!
State/province [28]
0
0
Pleven
Query!
Country [29]
0
0
Bulgaria
Query!
State/province [29]
0
0
Plovdiv
Query!
Country [30]
0
0
Bulgaria
Query!
State/province [30]
0
0
Ruse
Query!
Country [31]
0
0
Bulgaria
Query!
State/province [31]
0
0
Shumen
Query!
Country [32]
0
0
Bulgaria
Query!
State/province [32]
0
0
Sofia
Query!
Country [33]
0
0
Bulgaria
Query!
State/province [33]
0
0
Targovisthe
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Ontario
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Quebec
Query!
Country [36]
0
0
Chile
Query!
State/province [36]
0
0
Metropolitana
Query!
Country [37]
0
0
Chile
Query!
State/province [37]
0
0
Valparaiso
Query!
Country [38]
0
0
Chile
Query!
State/province [38]
0
0
X Region
Query!
Country [39]
0
0
Czechia
Query!
State/province [39]
0
0
Czech Republic
Query!
Country [40]
0
0
Czechia
Query!
State/province [40]
0
0
Brno
Query!
Country [41]
0
0
Czechia
Query!
State/province [41]
0
0
Ceska Lipa
Query!
Country [42]
0
0
Czechia
Query!
State/province [42]
0
0
Ostrava- Moravska Ostrava
Query!
Country [43]
0
0
Czechia
Query!
State/province [43]
0
0
Praha 4
Query!
Country [44]
0
0
Estonia
Query!
State/province [44]
0
0
Parnu
Query!
Country [45]
0
0
Estonia
Query!
State/province [45]
0
0
Tallinn
Query!
Country [46]
0
0
Israel
Query!
State/province [46]
0
0
Haifa
Query!
Country [47]
0
0
Israel
Query!
State/province [47]
0
0
Jerusalem
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Tel-Hashomer
Query!
Country [49]
0
0
Korea, Republic of
Query!
State/province [49]
0
0
Incheon
Query!
Country [50]
0
0
Korea, Republic of
Query!
State/province [50]
0
0
Daegu
Query!
Country [51]
0
0
Korea, Republic of
Query!
State/province [51]
0
0
Gwangju
Query!
Country [52]
0
0
Korea, Republic of
Query!
State/province [52]
0
0
Seoul
Query!
Country [53]
0
0
Latvia
Query!
State/province [53]
0
0
Riga
Query!
Country [54]
0
0
Lithuania
Query!
State/province [54]
0
0
Alytus
Query!
Country [55]
0
0
Lithuania
Query!
State/province [55]
0
0
Kaunas
Query!
Country [56]
0
0
Lithuania
Query!
State/province [56]
0
0
Siauliai
Query!
Country [57]
0
0
Mexico
Query!
State/province [57]
0
0
Coahuila
Query!
Country [58]
0
0
Mexico
Query!
State/province [58]
0
0
Distrito Federal
Query!
Country [59]
0
0
Mexico
Query!
State/province [59]
0
0
Jalisco
Query!
Country [60]
0
0
Mexico
Query!
State/province [60]
0
0
Sinaloa
Query!
Country [61]
0
0
Mexico
Query!
State/province [61]
0
0
Yucatan
Query!
Country [62]
0
0
Mexico
Query!
State/province [62]
0
0
Chihuahua
Query!
Country [63]
0
0
Mexico
Query!
State/province [63]
0
0
San Luis Potosi
Query!
Country [64]
0
0
Peru
Query!
State/province [64]
0
0
Arequipa
Query!
Country [65]
0
0
Peru
Query!
State/province [65]
0
0
Lima
Query!
Country [66]
0
0
Philippines
Query!
State/province [66]
0
0
Batangas
Query!
Country [67]
0
0
Philippines
Query!
State/province [67]
0
0
Davao DEL SUR
Query!
Country [68]
0
0
Philippines
Query!
State/province [68]
0
0
Iloilo
Query!
Country [69]
0
0
Philippines
Query!
State/province [69]
0
0
Metro Manila
Query!
Country [70]
0
0
Philippines
Query!
State/province [70]
0
0
Cebu City
Query!
Country [71]
0
0
Philippines
Query!
State/province [71]
0
0
Davao
Query!
Country [72]
0
0
Philippines
Query!
State/province [72]
0
0
Iloilo City
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Malopolska
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
WOJ Mazowieckie
Query!
Country [75]
0
0
Poland
Query!
State/province [75]
0
0
Bydgoszcz
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Bytom
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Elblag
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Gdynia
Query!
Country [79]
0
0
Poland
Query!
State/province [79]
0
0
Katowice
Query!
Country [80]
0
0
Poland
Query!
State/province [80]
0
0
Lodz
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Nadarzyn
Query!
Country [82]
0
0
Poland
Query!
State/province [82]
0
0
Poznan
Query!
Country [83]
0
0
Poland
Query!
State/province [83]
0
0
Warszawa
Query!
Country [84]
0
0
Poland
Query!
State/province [84]
0
0
Wroclaw
Query!
Country [85]
0
0
Romania
Query!
State/province [85]
0
0
Cluj
Query!
Country [86]
0
0
Romania
Query!
State/province [86]
0
0
Covasna
Query!
Country [87]
0
0
Romania
Query!
State/province [87]
0
0
Maramures
Query!
Country [88]
0
0
Romania
Query!
State/province [88]
0
0
Bucuresti
Query!
Country [89]
0
0
Romania
Query!
State/province [89]
0
0
Galati
Query!
Country [90]
0
0
Romania
Query!
State/province [90]
0
0
Iasi
Query!
Country [91]
0
0
Russian Federation
Query!
State/province [91]
0
0
Karelia Republic
Query!
Country [92]
0
0
Russian Federation
Query!
State/province [92]
0
0
Kemerovo
Query!
Country [93]
0
0
Russian Federation
Query!
State/province [93]
0
0
Moscow
Query!
Country [94]
0
0
Russian Federation
Query!
State/province [94]
0
0
Novosibirsk
Query!
Country [95]
0
0
Russian Federation
Query!
State/province [95]
0
0
Orenburg
Query!
Country [96]
0
0
Russian Federation
Query!
State/province [96]
0
0
Ryazan
Query!
Country [97]
0
0
Russian Federation
Query!
State/province [97]
0
0
Saint Petersburg
Query!
Country [98]
0
0
Russian Federation
Query!
State/province [98]
0
0
Samara
Query!
Country [99]
0
0
Russian Federation
Query!
State/province [99]
0
0
Saratov
Query!
Country [100]
0
0
Russian Federation
Query!
State/province [100]
0
0
Smolensk
Query!
Country [101]
0
0
Russian Federation
Query!
State/province [101]
0
0
Yaroslavl
Query!
Country [102]
0
0
South Africa
Query!
State/province [102]
0
0
FREE State
Query!
Country [103]
0
0
South Africa
Query!
State/province [103]
0
0
Gauteng
Query!
Country [104]
0
0
South Africa
Query!
State/province [104]
0
0
Kwazulu-natal
Query!
Country [105]
0
0
South Africa
Query!
State/province [105]
0
0
Western CAPE
Query!
Country [106]
0
0
Spain
Query!
State/province [106]
0
0
A Coruna
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Barcelona
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Madrid
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
Malaga
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Sevilla
Query!
Country [111]
0
0
Taiwan
Query!
State/province [111]
0
0
Taiwan ROC
Query!
Country [112]
0
0
Taiwan
Query!
State/province [112]
0
0
Hualien
Query!
Country [113]
0
0
Taiwan
Query!
State/province [113]
0
0
Kaohsiung
Query!
Country [114]
0
0
Taiwan
Query!
State/province [114]
0
0
Taipei
Query!
Country [115]
0
0
Taiwan
Query!
State/province [115]
0
0
Taoyuan County
Query!
Country [116]
0
0
Thailand
Query!
State/province [116]
0
0
Rajthevi
Query!
Country [117]
0
0
Thailand
Query!
State/province [117]
0
0
Bangkok
Query!
Country [118]
0
0
Thailand
Query!
State/province [118]
0
0
Songkhla
Query!
Country [119]
0
0
Turkey
Query!
State/province [119]
0
0
Ankara
Query!
Country [120]
0
0
Turkey
Query!
State/province [120]
0
0
Samsun
Query!
Country [121]
0
0
Turkey
Query!
State/province [121]
0
0
Sivas
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
WEST Midlands
Query!
Country [123]
0
0
United Kingdom
Query!
State/province [123]
0
0
Cannock
Query!
Country [124]
0
0
United Kingdom
Query!
State/province [124]
0
0
Leeds
Query!
Country [125]
0
0
United Kingdom
Query!
State/province [125]
0
0
Liverpool
Query!
Country [126]
0
0
United Kingdom
Query!
State/province [126]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To assess the efficacy of tofacitinib monotherapy or tofacitinib with methotrexate as
compared to adalimumab with methotrexate. To compare the efficacy of tofacitinib monotherapy
compared to tofacitinib combined with methotrexate. To compare effects on all health outcomes
measures in the study. To evaluate the safety and tolerability of tofacitinib and adalimumab.
To evaluate the safety of the zoster vaccine given prior to the initiation of tofacitinb or
adalimumab.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02187055
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02187055
Download to PDF